This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
by Ahan Chakraborty
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
by Kanishka Das
Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
AZNPositive Net Change RHHBYPositive Net Change BMYPositive Net Change MRKNegative Net Change
pharmaceuticals
UnitedHealth vs. Molina: Which Managed Care Stock Is the Better Bet?
by Rajshree Sipani
MOH's Medicaid focus, dual-eligible expansion and stronger share gains make it stand out against UNH in managed care.
UNHNegative Net Change MOHNegative Net Change
artificial-intelligence dental dividend healthcare hmo hospitals insurance insurance-premium medical pharmaceuticals smart-health staffing
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
by Sundeep Ganoria
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
BMYPositive Net Change MRKNegative Net Change AGENPositive Net Change IOVANegative Net Change
biotechs cell-therapy medical pharmaceuticals
AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication
by Zacks Equity Research
ABBV's Decnupaz wins FDA approval for BPDCN, adding its first blood cancer ADC and a new option for an ultra-rare aggressive malignancy.
ABBVNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
by Kinjel Shah
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
JNJNegative Net Change AMGNPositive Net Change TEVAPositive Net Change PTGXNegative Net Change
pharmaceuticals
Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion
by Shaun Pruitt
Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.
LLYNegative Net Change AMZNNegative Net Change AAPLNegative Net Change MSFTPositive Net Change PFEPositive Net Change NVOPositive Net Change AMGNPositive Net Change NVDANegative Net Change
investing large-cap medical pharmaceuticals
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
by Ekta Bagri
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
ADMAPositive Net Change NTLAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts
by Zacks Equity Research
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
SNYNegative Net Change BMYPositive Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
by Zacks Equity Research
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals